Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma...
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
About this item
Full title
Author / Creator
Albiges, Laurence , Gurney, Howard , Atduev, Vagif , Suarez, Cristina , Climent, Miguel A , Pook, David , Tomczak, Piotr , Barthelemy, Philippe , Lee, Jae Lyun , Stus, Viktor , Ferguson, Thomas , Wiechno, Pawel , Gokmen, Erhan , Lacombe, Louis , Gedye, Craig , Perini, Rodolfo F , Sharma, Manish , Peng, Xiang and Lee, Chung-Han
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Immunotherapy-based combinations including pembrolizumab plus lenvatinib are the standard of care for patients with first-line clear-cell renal cell carcinoma, but these combinations are not well characterised in non-clear-cell renal cell carcinoma. We aimed to assess the activity and safety of pembrolizumab plus lenvatinib as a first-line treatmen...
Alternative Titles
Full title
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2838252422
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2838252422
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(23)00276-0
